PROK — what changed in the latest 10-Q
A section-by-section comparison of PROK's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-10 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +25 | −15 | ~9 | 56 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | +1 | 0 | ~2 | 4 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-10
increase in research costs of $0.6 million related to ongoing mechanism of action studies of rilparencel; and
increase in professional fees of approximately $0.4 million related to the use of consultants as we begin to prepare for regulatory filings.
decreases in cash-based compensation of approximately $0.6 million related to reductions in severance amounts paid for terminated employees; and
decreases in professional fees and other operating costs of approximately $0.4 million driven by ongoing initiatives including the Domestication and Restructuring transactions in 2025.
The following table summarizes our results of operations for the six months ended June 30, 2026 and 2025 (in thousands):
Text removed vs the prior filing · source: 10-Q · 2026-05-15
increase in compensation costs of approximately $1.2 million due to the hiring of additional personnel; offset by
decrease in clinical study costs of $1.6 million related to clinical trials that have been completed or terminated.
decreases in professional fees and other operating costs of approximately $1.4 million driven by ongoing initiatives including the Domestication and Restructuring transactions in 2025; and
decreases in cash-based compensation of approximately $0.5 million related to reductions in severance amounts paid for terminated employees.
Since our inception, we have not recognized any revenue and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. From our inception thro…
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-10
may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice